|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We discovered significantly low expression of Par-4 in the tumor tissue, which was positively correlated with high expression of GRP78 (glucose-regulated protein 78).
|
28720068 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, IKM5 amplified the expression and nuclear translocation of tumor suppressor Par-4 to control NF-kB-mediated pro-EMT activities.
|
31175498 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, these results indicate that residual breast cancer tumor cell survival and recurrence requires circumventing Foxo-driven Par-4 upregulation and suggest that approaches to enforce Par-4 expression may prevent residual cell survival and recurrence.<i></i>.
|
29330285 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of tumor remnants showed that KPT-330 disrupted the interaction between CRM-1 and PAR-4, activated PAR-4 signaling, and reduced proliferation of tumor cells.
|
23089203 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4 is one such tumor suppressor which is unique in its ability to selectively induce apoptosis in cancer cells while leaving the normal cells unaffected.
|
25001535 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor Par-4 is a novel integral player in the PTEN network.
|
19625770 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PAR4 may acts as a tumor suppressor in lung adenocarcinoma.
|
23886184 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, WIN effects were not associated with a canonical apoptotic pathway, as demonstrated by the absence of specific features, and only the addition of TRAIL to WIN-treated cells led to apoptotic death probably mediated by up-regulation of the tumor suppressor factor PAR-4, whose levels increased after WIN treatment, and by the translocation of GRP78 on cell surface.
|
24795528 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor Par-4 is an important negative regulator of the canonical NF-kappaB pathway and is highly expressed in prostate.
|
19470463 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, recombinant Par-4 inhibits the growth of tumors in mice.
|
22552839 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4-overexpressing tumors exhibited a bystander effect on wild-type tumors growing distally in the same mouse.
|
21555373 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral administration of WA to mice with xenograft tumors restores FOXO3a-mediated Par-4 functions and results in inhibited tumor growth.
|
26913603 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression.
|
11585763 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis.
|
9989812 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using an epigenome editing approach to reexpress Par-4 by specifically reversing the histone modifications found in recurrent tumors, we found that Par-4 reexpression sensitized recurrent tumors to chemotherapy in vitro and in vivo.
|
30148456 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Importantly, restoration of Par-4 levels to normal in Ras-transformed cells makes these cells sensitive to the pro-apoptotic actions of tumor necrosis factor-alpha under conditions in which PI 3-kinase is inhibited and also severely impairs colony formation in soft agar and tumor development in nude mice, as well as increases the sensitivity of these tumors to camptothecin.
|
10562548 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer-associated fibroblasts promote cancer cell growth through a miR-7-RASSF2-PAR-4 axis in the tumor microenvironment.
|
27901488 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This review emphasizes the role of Par-4/SAC in apoptosis and tumor resistance.
|
18836307 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For instance, we demonstrate using ChIP-seq analysis that estrogen downregulate tumor suppressor Par-4 in hormone-dependent cells by directly binding to its DNA regulatory elements and inhibiting estrogen signaling could reinstate Par-4 apoptosis-inducing abilities.
|
28008141 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results therefore identify a key strd-1/STRAD-independent function of par-4/LKB1 in polarity establishment that is likely to be important for tumour suppression in humans.
|
20110331 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis.
|
28076793 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After several months the indolent WT1-LNCaP cells became proliferative forming small tumors lacking par-4 protein.
|
14767530 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have uncovered a novel mechanism of 3-azidoWA induced extracellular pro-apoptotic candidate tumor suppressor Par-4 protein stimulation in conditioned media and also noticed a concomitant marked reduction in pAkt and pERK signaling by immunoblot analysis.
|
22962598 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Breast cancer cell proliferation, cancer cell-induced endothelial tube formation in vitro, and tumour growth in vivo were studied in the presence of protease-activated receptor 1-stimulated platelet releasate (PAR1-PR; rich in pro-angiogenic factors) or PAR4-PR (rich in anti-angiogenic factors).
|
28697175 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.
|
24992930 |
2014 |